Regan, M. M., Walley, B. A., Spazzapan, S., Parmer, V., Ruhstaller, T., Abdi, E. A., Gelber, R. D., Coates, A. S., Goldhirsch, A., Pagani, O., Francis, P. A., Fleming, G. F., Lang, I., Gomez, H. L., Colleoni, M., Tondini, C., Pinotti, G., Salim, M.. Oxford University Press; 2017. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.

Green, M. D., Francis, P. A., Gebski, V., Harvey, V., Karapetis, C., Chan, A., Snyder, R., Fong, A., Basser, R., Forbes, J. F., Australian New Zealand Breast Cancer Trials Group. Oxford University Press; 2009. Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer.

McCarthy, N., Boyle, F., Gebski, V., Veillard, A. S., Zannino, D., Wilcken, N., Reaby, L., Lindsay, D. F., Badger, H. D., Forbes, J. F., Zdenkowski, N., Bull, J., Leong, E., Simpson, A., Kannourakis, G., Francis, P. A., Chirgwin, J., Abdi, E.. Elsevier; 2014. Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).